Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients

Journal of the American Society of Nephrology

Volumn 20, Issue 4, 2009, Pages 872-881

  Chan, Kevin E ^a,c   Lazarus, J Michael ^a   Thadhani, Ravi ^b   Hakim, Raymond M ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDICATION; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL; THROMBOEMBOLISM; THROMBOSIS; VASCULAR ACCESS;

EID: 65349189718     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008080824     Document Type: Article

References (48)

1. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115: 813-818, 2007
2. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update-Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363-2372, 2006
3. Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107: 1692-1711, 2003
4. Hennekens CH, Dyken ML, Fuster V: Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 96: 2751-2753, 1997
5. Hirsch J, Guyatt G, Albers GW, Schunermann HJ: The Seventh ACCP Conference on Antithromobotic and Thrombolytic Therapy. Chest 126: 172S-173S, 2004
6. US Renal Data Systems: USRDS 2003 Annual Data Report, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003
7. Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, Gillespie BW, Young EW: Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 50: 602-611, 2007
8. Miller LM, Hopman WM, Garland JS, Yeates KE, Pilkey RM: Cardioprotective medication use in hemodialysis patients. Can J Cardiol 22: 755-760, 2006
9. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998
10. Bennett WM: Should dialysis patients ever receive warfarin and for what reasons? Clin J Am Soc Nephrol 1: 1357-1359, 2006
11. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial. J Am Soc Nephrol 13: 2331-2337, 2002
12. Zellweger M, Bouchard J, Raymond-Carrier S, Laforest-Renald A, Querin S, Madore F: Systemic anticoagulation and prevention of hemodialysis catheter malfunction. ASAIO J 51: 360-365, 2005
13. Traynor JP, Walbaum D, Woo YM, Teenan P, Fox JG, Mactier RA: Low-dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrol Dial Transplant 16: 645, 2001
14. Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO: A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59: 1935-1942, 2001
15. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 299: 2164-2171, 2008
16. Elliott MJ, Zimmerman D, Holden RM: Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am J Kidney Dis 50: 433-440, 2007
17. Holden RM, Harman GJ, Wang M, Holland D, Day AG: Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3: 105-110, 2008
18. Janssen MJ, van der Meulen J: The bleeding risk in chronic haemodialysis: Preventive strategies in high-risk patients. Neth J Med 48: 198-207, 1996
19. Sreedhara R, Itagaki I, Lynn B, Hakim RM: Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 25: 555-563, 1995
20. Majerus P: Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics, 11th Ed., edited by Brunton L, New York, McGraw-Hill, 2006, pp 1467-1488
21. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15: 2857-2867, 2004
22. Yevzlin AS, Sanchez RJ, Hiatt JG, Washington MH, Wakeen M, Hofmann RM, Becker YT: Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial 20: 351-354, 2007
23. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14: 2313-2321, 2003
24. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
25. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
26. Holden RM, Booth SL: Vascular calcification in chronic kidney disease: The role of vitamin K. Nat Clin Pract Nephrol 3: 522-523, 2007
27. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993
28. Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG: Dose of hemodi- alysis and survival: Differences by race and sex. JAMA 280: 1764-1768, 1998
29. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287: 1548-1555, 2002
30. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342: 1887-1892, 2000
31. PERL 5.005 [Computer program], 1998. Available at: http://www.cpan.org/ src/README.html. Accessed November 1, 2007
32. Food and Drug Administration: Electronic Orange Book (EOB) Query Data Files; 2007. Available at: http://www.fda.gov/cder/orange/obreadme.htm. Accessed November 1, 2007
33. Hietaniemia J: String::Approx - Perl extension for approximate matching (fuzzy matching); 2005. Available at: http://search.cpan.org/~jhi/String-Approx- 3.26/Approx.pm. Accessed November 1, 2007
34. Grannis SJ, Overhage JM, McDonald C: Real world performance of approximate string comparators for use in patient matching. Medinfo 11: 43-47, 2004
35. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: 373-383, 1987
36. Department of Health and Human Services: The International Classification of Diseases, 9th Rev., Clinical Modification: ICD-9-CM. Washington, DC: Government Printing Office, 1980. DHHS Publication No. 80-1260
37. Robinson JR, Young TK, Roos LL, Gelskey DE: Estimating the burden of disease: Comparing administrative data and self-reports. Med Care 35: 932-947, 1997
38. Luthi JC, Troillet N, Eisenring MC, Sax H, Burnand B, Quan H, Ghali W: Administrative data outperformed single-day chart review for comorbidity measure. Int J Qual Health Care 19: 225-231, 2007
39. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 1130-1139, 2005
40. Quan H, Parsons GA, Ghali WA: Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 40: 675-685, 2002
41. Chaudhry S, Jin L, Meltzer D: Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med Care 43: 607-615, 2005
42. Miskulin DC, Martin AA, Brown R, Fink NE, Coresh J, Powe NR, Zager PG, Meyer KB, Levey AS: Predicting 1 year mortality in an outpatient haemodialysis population: A comparison of comorbidity instruments. Nephrol Dial Transplant 19: 413-420, 2004
43. van Manen JG, Korevaar JC, Dekker FW, Boeschoten EW, Bossuyt PM, Krediet RT: How to adjust for comorbidity in survival studies in ESRD patients: A comparison of different indices. Am J Kidney Dis 40: 82-89, 2002
44. Lowrie EG, Teng M, Lacson E, Lew N, Lazarus JM, Owen WF: Association between prevalent care process measures and facility-specific mortality rates. Kidney Int 60: 1917-1929, 2001
45. Rosenbaum PR: The central role of the propensity score in observational studies for causal effect. Biometrika 70: 41-55, 1983
46. Imbens G: The role of propensity score in estimating dose-response in observational studies for causal effect. Biometrika 3: 706-710, 2000
47. Kosanke J BE: Gmatch: SAS macro, 2004. Available at: http://mayoresearch. mayo.edu/mayo/research/biostat/upload/gmatch.sas. Accessed December 1, 2007
48. Rubin D: Matching to remove bias in observational studies. Biometrics 159-183, 1973